Modulation of heart function by Muscle LIM protein-mediated mechanotransduction
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction
批准号:
10503955
负责人:
Yibing Qyang
金额:
$41.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2026-06-30
关键词:
3 year oldActinsActomyosinAffectAffinityAutophagocytosisBiomechanicsBiopsyBioreactorsCalcineurinCalcineurin inhibitorCalciumCardiacCardiac MyocytesCardiac MyosinsComplexComputer ModelsCoupledDevelopmentDiastoleDisinhibitionEventExtracellular MatrixFamilial Hypertrophic CardiomyopathyFiberFibroblastsFoundationsFutureGenerationsGenesGeneticHeart DiseasesHeart HypertrophyHeart failureHeterozygoteHumanHyperactivityHypertrophic CardiomyopathyHypertrophyImpairmentIndividualInheritedInterventionInvestigationLasersLeftLeft Ventricular HypertrophyLengthLysosomesMechanicsMediatingMicrofilamentsMolecularMuscleMuscle ContractionMutationMyocardial dysfunctionMyocardiumMyosin ATPaseMyosin Heavy ChainsNonsense CodonNuclearObstructionPPP3CA geneParentsPathologicPathway interactionsPatientsPeptide HydrolasesPersonsPharmacologyPhenotypePhysiologicalPoint MutationProductionProtein IsoformsProteinsRelaxationRepressionRodentRoleSarcomeresSignal TransductionSkinSomatic CellStem Cell FactorStressStretchingSystemSystoleT-Cell ActivationTestingTissuesUbiquitinVentricularbasecardiac tissue engineeringdesigndisease phenotypeheart functionhuman diseaseimprovedinduced pluripotent stem cellinduced pluripotent stem cell derived cardiomyocytesinnovationinsightmalemechanical propertiesmechanical stimulusmechanotransductionmouse modelmulticatalytic endopeptidase complexmuscle LIM proteinmutantnon-muscle myosin heavy chain-Bnovelnovel strategiesnovel therapeuticsnuclear factors of activated T-cellsplasma protein Zpreventprobandprotein degradationrecruitresponsescaffoldsudden cardiac deathtransmission process
中文摘要
家族性肥厚型心肌病(HCM)是最常见的遗传性心脏病,通常由
通过编码肌节蛋白的基因突变来调节心脏收缩能力。HCM的表现包括
左心室肥厚和心力衰竭、心律失常和心脏性猝死。机械转导
感知肌节作用力异常并导致病理性重塑的机制
在肥厚型心肌病中仍然知之甚少,从而抑制了新疗法的有效开发。我们的发现
是基于对一名肥厚型心肌炎患者的严重表型和第二次基因改变的洞察
肌节机械感应蛋白。我们有效地从患者特异性诱导的心肌细胞中获得了
多能干细胞(IPSC-CMS)和通过种植IPSC-CMS发展成强大的工程心脏组织(EHTS
一种具有天然心脏纤维排列的激光切割支架,用于在两边研究人类心脏力学生物学
细胞和组织水平。与肌肉收缩和疾病救援的计算建模相结合
通过基因编辑和药物干预,我们已经确定了一种新的机械转导
HCM中的通路。肌球蛋白肌瘤突变引起的肌动球蛋白交叉桥形成增强
重链(MYH7)导致了更多的力量产生,当再加上较慢的抽搐放松时,
破坏了Z盘处的肌肉LIM蛋白(MLP)拉伸传感复合体的稳定性。随后减少了
肌瘤MLP水平可解除钙调神经磷酸酶激活T细胞核因子(NFAT)信号的抑制,
促进了心肌肥大。通过以下两种途径之一减轻肌动球蛋白交叉桥的形成
通过遗传或药物手段,我们缓解了Z盘应力,防止了肥大的发展
与肉瘤突变有关。这项建议将剖析收缩和舒张期Z盘应力的作用
在调节MLP机械感觉复合体方面并阐明介导MLP的分子机制
MLP对钙调神经磷酸酶/NFAT的抑制以及拉伸传感对MLP蛋白的降解。我们最近做了
开发了一种新的生物反应器,可以将EHTS暴露在精确的规定后负载中,所以我们可以测试
假设在较高的后载下,交叉桥产生的较高的收缩力会破坏MLP在
Z-Disc和激活收缩期间的肥大信号。此外,EHTS将在以下条件下接受文化
恒定长度或舒张期拉伸以模拟脑室充盈的状态。经过反复拉伸,EHTS
将接受肥大信号检查。我们将揭开MLP的机械性洞察力
在Z-Disc压力下退化。此外,我们还将剖析MLP抑制的分子机制
钙调神经磷酸酶/NFAT在收缩和舒张期的肥大反应。A的分子机制的阐明
常见的肌节收缩/MLP/钙调神经磷酸酶机械转导通路将有助于设计新的
通过稳定Z-Disk MLP机械感觉对广泛心力衰竭患者的潜在策略
很复杂。
英文摘要
Familial hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and is typically caused
by mutations in genes encoding sarcomeric proteins that regulate cardiac contractility. HCM manifestations include
left ventricular hypertrophy and heart failure, arrythmias, and sudden cardiac death. The mechanotransduction
mechanism by which dysregulated sarcomeric force production is sensed and leads to pathological remodeling
remains poorly understood in HCM, thereby inhibiting the efficient development of new therapeutics. Our discovery
was based on insights from a severe phenotype of an individual with HCM and a second genetic alteration in a
sarcomeric mechano-sensing protein. We effectively derived cardiomyocytes from patient-specific induced
pluripotent stem cells (iPSC-CMs) and developed robust engineered heart tissues (EHTs) by seeding iPSC-CMs into
a laser-cut scaffold possessing native cardiac fiber alignment, for studying human cardiac mechanobiology at both
cellular and tissue levels. Coupled with computational modeling for muscle contraction and rescue of disease
phenotype via gene editing and pharmacological interventions, we have identified a new mechanotransduction
pathway in HCM. Enhanced actomyosin crossbridge formation caused by sarcomeric mutations in cardiac myosin
heavy chain (MYH7) led to increased force generation, which when coupled with slower twitch relaxation,
destabilized the muscle LIM protein (MLP) stretch-sensing complex at the Z-disc. Subsequent reduction in the
sarcomeric MLP level caused disinhibition of calcineurin–nuclear factor of activated T-cells (NFAT) signaling,
which promoted cardiac hypertrophy. By mitigating enhanced actomyosin crossbridge formation through either
genetic or pharmacological means, we alleviated stress at the Z-disc, preventing the development of hypertrophy
associated with sarcomeric mutations. This proposal will dissect the roles of systolic and diastolic Z-disc stress
in modulating the MLP mechanosensory complex and elucidate the molecular mechanisms that mediate the
repression of calcineurin/NFAT by MLP as well as MLP protein degradation by stretch-sensing. We have recently
developed a new bioreactor that can expose EHTs to precisely prescribed afterloads, so we can test the
hypothesis that higher systolic forces produced by crossbridges under higher afterloads destabilize MLP at the
Z-disc and activate hypertrophic signaling during systole. Additionally, EHTs will be subjected to culture under
conditions of either constant length or diastolic stretch to mimic ventricular filling. After repeated stretching, EHTs
will be examined for hypertrophic signaling. We will unravel mechanistic insights into how saromeric MLP is
degraded in response to Z-disc stress. In addition, we will dissect molecular mechanisms by which MLP inhibits
calcineurin/NFAT hypertrophic responses in systole and diastole. Elucidation of the molecular mechanisms of a
common sarcomeric contraction/MLP/calcineurin mechanotransduction pathway will help to design novel
strategies for a wide spectrum of heart failure patients potentially through stabilizing the Z-disk MLP mechanosensory
complex.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction
-
批准号:10645223
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2022
-
负责人:Yibing Qyang
-
依托单位:
Development of HLA engineered universal vascular grafts from human iPSCs
-
批准号:10457467
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2021
-
负责人:Yibing Qyang
-
依托单位:
Development of HLA engineered universal vascular grafts from human iPSCs
-
批准号:10685550
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2021
-
负责人:Yibing Qyang
-
依托单位:
Development of HLA engineered universal vascular grafts from human iPSCs
-
批准号:10298018
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2021
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10841794
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10622873
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10414459
-
项目类别:
-
资助金额:$6.19万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10636647
-
项目类别:
-
资助金额:$66.43万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10439796
-
项目类别:
-
资助金额:$66.43万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10189694
-
项目类别:
-
资助金额:$66.43万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
-
批准号:10630420
-
项目类别:
-
资助金额:$6.38万
-
财政年份:2020
-
负责人:Yibing Qyang
-
依托单位:
Human tissue-engineered blood vessels using induced pluripotent stem cells
-
批准号:8529043
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2013
-
负责人:Yibing Qyang
-
依托单位:
Human tissue-engineered blood vessels using induced pluripotent stem cells
-
批准号:9100857
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2013
-
负责人:Yibing Qyang
-
依托单位:
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem Cells
-
批准号:8303446
-
项目类别:
-
资助金额:$9.84万
-
财政年份:2010
-
负责人:Yibing Qyang
-
依托单位:
Derivation and Functional Characterization of Heart Cells from Human Embryonic an
-
批准号:8106224
-
项目类别:
-
资助金额:$9.84万
-
财政年份:2010
-
负责人:Yibing Qyang
-
依托单位:
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem Cells
-
批准号:8677951
-
项目类别:
-
资助金额:$9.84万
-
财政年份:2010
-
负责人:Yibing Qyang
-
依托单位:
Derivation and Functional Characterization of Heart Cells from Human Embryonic an
-
批准号:7870865
-
项目类别:
-
资助金额:$9.55万
-
财政年份:2010
-
负责人:Yibing Qyang
-
依托单位:
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem Cells
-
批准号:8473266
-
项目类别:
-
资助金额:$9.84万
-
财政年份:2010
-
负责人:Yibing Qyang
-
依托单位:
海外基金